Entry Detail
| General information | |
| Database: | DB00949 |
| Objective: | Pazopanib is a small molecule inhibitor of kinases principally including vascular endothelial growth factor receptors1, 2, and 3; plateletderived growth factor receptors¦Á and ¦Â; and cKit. they previously reported a tumor response rate of 49% in patients with advanced differentiated thyroid cancer and 0% in patients with advanced anaplastic thyroid cancer. The present report details results of pazopanib therapy in advanced medullary thyroid cancer (MTC). OBJECTIVE, DESIGN, SETTING, PATIENTS, INTERVENTION, AND OUTCOME MEASURES: Having noted preclinical activity of pazopanib in MTC, patients with advanced MTC who had disease progression within the preceding 6 months were accrued to this multiinstitutionalphase II clinical trial to assess tumor response rate (by Response Evaluation Criteria In Solid Tumors criteria) and safety of pazopanib given orally once daily at 800 mg until disease progression or intolerability |
| Authors: | Bible KC, et al |
| Title: | A multicenterphase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. |
| Journal: | J Clin Endocrinol Metab |
| Year: | 2014 |
| PMID: | 24606083 |
| Trial Design | |
| Clinical Trial Id: | NCT00625846 |
| Agent: | pazopanib |
| Target: | Plateletderived growth factor receptor Mast/stem cell growth factor receptor Vascular endothelial growth factor receptor 2 |
| Cancer Type: | thyroid cancer |
| Cancer Subtype: | medullary thyroid carcinoma. |
| Therapy Type: | mono |
| Therapeutic Combination Type: | NA |
| Therapeutic Combination Content: | NA |
| Study Type: | A multicenterphase II trial |
| Key Patients Feature: | patients with advanced MTC who had disease progression within the preceding 6 months |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | pazopanib were given orally once daily at 800 mg until disease progression or intolerability. |
| Primary End Point: | efficacy and safety |
| Secondary End Point: | NA |
| Patients Number: | 35 |
| Trial Results | |
| DLT_MTD: | NA |
| Objective Response Rate: | 14.30% |
| Disease Control Rate: | 37.30% |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | 9.4 months |
| Median OS A vs. C: | 19.9 months |
| Adverse Event(agent arm): | The most Common Terminology Criteria for Adverse Events (CTCAE v3.0, grades 3-5) toxicities were fatigue (14%) and diarrhea (9%) |
| Conclusions: | Pazopanib has promising clinical activity in metastatic MTC with overall manageable toxicities |